Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
Sioulas VD, Schiavone MB, Kadouri D, Zivanovic O, Roche KL, O'Cearbhaill R, Abu-Rustum NR, Levine DA, Sonoda Y, Gardner GJ, Leitao MM Jr, Chi DS. Sioulas VD, et al. Among authors: roche kl. Gynecol Oncol. 2017 Apr;145(1):15-20. doi: 10.1016/j.ygyno.2017.02.023. Epub 2017 Feb 21. Gynecol Oncol. 2017. PMID: 28238354 Free PMC article.
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Fader AN, Bergstrom J, Jernigan A, Tanner EJ 3rd, Roche KL, Stone RL, Levinson KL, Ricci S, Wethingon S, Wang TL, Shih IM, Yang B, Zhang G, Armstrong DK, Gaillard S, Michener C, DeBernardo R, Rose PG. Fader AN, et al. Among authors: roche kl. Gynecol Oncol. 2017 Oct;147(1):85-91. doi: 10.1016/j.ygyno.2017.07.127. Epub 2017 Jul 30. Gynecol Oncol. 2017. PMID: 28768570
Outcomes Associated With a Five-Point Surgical Site Infection Prevention Bundle in Women Undergoing Surgery for Ovarian Cancer.
Lippitt MH, Fairbairn MG, Matsuno R, Stone RL, Tanner EJ 3rd, Wick EC, Angarita AC, Roche KL, Levinson KL, Bergstrom JE, Sinno AK, Curless MS, Wethington S, Temkin SM, Efron J, Hobson D, Fader AN. Lippitt MH, et al. Among authors: roche kl. Obstet Gynecol. 2017 Oct;130(4):756-764. doi: 10.1097/AOG.0000000000002213. Obstet Gynecol. 2017. PMID: 28885412
Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer.
Aviki EM, Lavery JA, Roche KL, Cowan R, Dessources K, Basaran D, Green AK, Aghajanian CA, O'Cearbhaill R, Jewell EL, Leitao MM Jr, Gardner GJ, Abu-Rustum NR, Sabbatini P, Bach PB. Aviki EM, et al. Among authors: roche kl. Gynecol Oncol. 2020 Nov;159(2):418-425. doi: 10.1016/j.ygyno.2020.07.104. Epub 2020 Aug 16. Gynecol Oncol. 2020. PMID: 32814642 Free PMC article.
Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study.
Plett H, Filippova OT, Garbi A, Kommoss S, Rosendahl M, Langstraat C, Phadnis S, Muallem MZ, Baert T, Chi DS, Aletti GD, Taran FA, Ramspott JP, Zivanovic O, du Bois A, Sonoda Y, Gardner G, Traut A, Roche KL, Harter P. Plett H, et al. Among authors: roche kl. Gynecol Oncol. 2020 Nov;159(2):434-441. doi: 10.1016/j.ygyno.2020.08.028. Epub 2020 Sep 9. Gynecol Oncol. 2020. PMID: 32919778 Free PMC article.
36 results